Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anca L Grosu

Showing results (141-150 of 174) with videos related to

Pageof 18
Sort By:
Journal of Applied Clinical Medical Physics|October 21, 2025
Decision-making between DCA and VMAT in Linac-based SRS for brain lesions: A dosimetric analysis based on tumor size and geometry and introduction of QasymLara Caglayan, Davide Scafa, Patrick Eich, et al.
Scientific Reports|March 13, 2021
The impact of the co-registration technique and analysis methodology in comparison studies between advanced imaging modalities and whole-mount-histology reference in primary prostate cancerConstantinos Zamboglou, Maria Kramer, Selina Kiefer, et al.
Cancers|November 27, 2021
PSMA-PET/MRI-Based Focal Dose Escalation in Patients with Primary Prostate Cancer Treated with Stereotactic Body Radiation Therapy (HypoFocal-SBRT): Study Protocol of a Randomized, Multicentric Phase III TrialConstantinos Zamboglou, Simon K B Spohn, Sonja Adebahr, et al.
Radiation Oncology (London, England)|October 5, 2022
Ex vivo γH2AX assay for tumor radiosensitivity in primary prostate cancer patients and correlation with clinical parametersIoana M Marinescu, Manuel Rogg, Simon Spohn, et al.
Radiation Oncology (London, England)|September 23, 2018
Correction to: Effect of radiochemotherapy on T2* MRI in HNSCC and its relation to FMISO PET derived hypoxia and FDG PETNicole Wiedenmann, Hatice Bunea, Hans C Rischke, et al.
Radiation Oncology (London, England)|August 31, 2018
Effect of radiochemotherapy on T2* MRI in HNSCC and its relation to FMISO PET derived hypoxia and FDG PETNicole Wiedenmann, Hatice Bunea, Hans C Rischke, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|October 25, 2024
ESTRO-EANO guideline on target delineation and radiotherapy for IDH-mutant WHO CNS grade 2 and 3 diffuse gliomaBrigitta G Baumert, Jaap P M Jaspers, Vera C Keil, et al.
Plos One|March 12, 2015
A novel miRNA-based predictive model for biochemical failure following post-prostatectomy salvage radiation therapyErica Hlavin Bell, Simon Kirste, Jessica L Fleming, et al.
Neuro-Oncology|September 22, 2023
Towards more Diversity in Neuro-oncology Leadership-the DivINe InitiativeSylvia C Kurz, Anja Stammberger, Steffen K Rosahl, et al.
Frontiers in Oncology|August 1, 2022
Intraindividual Comparison Between [<sup>18</sup>F] PSMA-1007 PET/CT and Multiparametric MRI for Radiotherapy Planning in Primary Prostate Cancer PatientsIoana M Marinescu, Simon K B Spohn, Selina Kiefer, et al.
Pageof 18

Showing results (141-150 of 174) with videos related to

Sort By:
Pageof 18
Journal of Applied Clinical Medical Physics|October 21, 2025
Decision-making between DCA and VMAT in Linac-based SRS for brain lesions: A dosimetric analysis based on tumor size and geometry and introduction of QasymLara Caglayan, Davide Scafa, Patrick Eich, et al.
Scientific Reports|March 13, 2021
The impact of the co-registration technique and analysis methodology in comparison studies between advanced imaging modalities and whole-mount-histology reference in primary prostate cancerConstantinos Zamboglou, Maria Kramer, Selina Kiefer, et al.
Cancers|November 27, 2021
PSMA-PET/MRI-Based Focal Dose Escalation in Patients with Primary Prostate Cancer Treated with Stereotactic Body Radiation Therapy (HypoFocal-SBRT): Study Protocol of a Randomized, Multicentric Phase III TrialConstantinos Zamboglou, Simon K B Spohn, Sonja Adebahr, et al.
Radiation Oncology (London, England)|October 5, 2022
Ex vivo γH2AX assay for tumor radiosensitivity in primary prostate cancer patients and correlation with clinical parametersIoana M Marinescu, Manuel Rogg, Simon Spohn, et al.
Radiation Oncology (London, England)|September 23, 2018
Correction to: Effect of radiochemotherapy on T2* MRI in HNSCC and its relation to FMISO PET derived hypoxia and FDG PETNicole Wiedenmann, Hatice Bunea, Hans C Rischke, et al.
Radiation Oncology (London, England)|August 31, 2018
Effect of radiochemotherapy on T2* MRI in HNSCC and its relation to FMISO PET derived hypoxia and FDG PETNicole Wiedenmann, Hatice Bunea, Hans C Rischke, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|October 25, 2024
ESTRO-EANO guideline on target delineation and radiotherapy for IDH-mutant WHO CNS grade 2 and 3 diffuse gliomaBrigitta G Baumert, Jaap P M Jaspers, Vera C Keil, et al.
Plos One|March 12, 2015
A novel miRNA-based predictive model for biochemical failure following post-prostatectomy salvage radiation therapyErica Hlavin Bell, Simon Kirste, Jessica L Fleming, et al.
Neuro-Oncology|September 22, 2023
Towards more Diversity in Neuro-oncology Leadership-the DivINe InitiativeSylvia C Kurz, Anja Stammberger, Steffen K Rosahl, et al.
Frontiers in Oncology|August 1, 2022
Intraindividual Comparison Between [<sup>18</sup>F] PSMA-1007 PET/CT and Multiparametric MRI for Radiotherapy Planning in Primary Prostate Cancer PatientsIoana M Marinescu, Simon K B Spohn, Selina Kiefer, et al.
Pageof 18